» Articles » PMID: 31824347

Can N-Methyl-D-Aspartate Receptor Hypofunction in Schizophrenia Be Localized to an Individual Cell Type?

Overview
Specialty Psychiatry
Date 2019 Dec 12
PMID 31824347
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Hypofunction of N-methyl-D-aspartate glutamate receptors (NMDARs), whether caused by endogenous factors like auto-antibodies or mutations, or by pharmacological or genetic manipulations, produces a wide variety of deficits which overlap with-but do not precisely match-the symptom spectrum of schizophrenia. In order to understand how NMDAR hypofunction leads to different components of the syndrome, it is necessary to take into account which neuronal subtypes are particularly affected by it in terms of detrimental functional alterations. We provide a comprehensive overview detailing findings in rodent models with cell type-specific knockout of NMDARs. Regarding inhibitory cortical cells, an emerging model suggests that NMDAR hypofunction in parvalbumin (PV) positive interneurons is a potential for this disease. PV interneurons display a selective vulnerability resulting from a combination of genetic, cellular, and environmental factors that produce pathological multi-level positive feedback loops. Central to this are two antioxidant mechanisms-NMDAR activity and perineuronal nets-which are themselves impaired by oxidative stress, amplifying disinhibition. However, NMDAR hypofunction in excitatory pyramidal cells also produces a range of schizophrenia-related deficits, in particular maladaptive learning and memory recall. Furthermore, NMDAR blockade in the thalamus disturbs thalamocortical communication, and NMDAR ablation in dopaminergic neurons may provoke over-generalization in associative learning, which could relate to the positive symptom domain. Therefore, NMDAR hypofunction can produce schizophrenia-related effects through an action on various different circuits and cell types.

Citing Articles

Glutamate levels and symptom burden in high-risk and first-episode schizophrenia: a dual-voxel study of the anterior cingulate cortex.

Fan L, Zhang Z, Ma X, Liang L, Wang Y, Yuan L J Psychiatry Neurosci. 2024; 49(6):E367-E376.

PMID: 39542650 PMC: 11573428. DOI: 10.1503/jpn.240094.


D-serine reconstitutes synaptic and intrinsic inhibitory control of pyramidal neurons in a neurodevelopmental mouse model for schizophrenia.

Zhang X, Xu L, Zhu X, Tang Z, Dong Y, Yu Z Nat Commun. 2023; 14(1):8255.

PMID: 38086803 PMC: 10716516. DOI: 10.1038/s41467-023-43930-8.


Behavioral and transcriptional effects of repeated electroconvulsive seizures in the neonatal MK-801-treated rat model of schizophrenia.

Lee J, Huh S, Park K, Kang N, Yu H, Park H Psychopharmacology (Berl). 2023; 241(4):817-832.

PMID: 38081977 DOI: 10.1007/s00213-023-06511-7.


The role of NMDARs in the anesthetic and antidepressant effects of ketamine.

Zhou L, Duan J CNS Neurosci Ther. 2023; 30(4):e14464.

PMID: 37680076 PMC: 11017467. DOI: 10.1111/cns.14464.


Potential Roles for the GluN2D NMDA Receptor Subunit in Schizophrenia.

Vinnakota C, Hudson M, Jones N, Sundram S, Hill R Int J Mol Sci. 2023; 24(14).

PMID: 37511595 PMC: 10380280. DOI: 10.3390/ijms241411835.


References
1.
GREIFENSTEIN F, Devault M, Yoshitake J, GAJEWSKI J . A study of a 1-aryl cyclo hexyl amine for anesthesia. Anesth Analg. 1958; 37(5):283-94. View

2.
Kegeles L, Abi-Dargham A, Zea-Ponce Y, Mann J, van Heertum R, Cooper T . Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry. 2000; 48(7):627-40. DOI: 10.1016/s0006-3223(00)00976-8. View

3.
Lipton S, Choi Y, Takahashi H, Zhang D, Li W, Godzik A . Cysteine regulation of protein function--as exemplified by NMDA-receptor modulation. Trends Neurosci. 2002; 25(9):474-80. DOI: 10.1016/s0166-2236(02)02245-2. View

4.
Bachiller A, Poza J, Gomez C, Molina V, Suazo V, Hornero R . A comparative study of event-related coupling patterns during an auditory oddball task in schizophrenia. J Neural Eng. 2014; 12(1):016007. DOI: 10.1088/1741-2560/12/1/016007. View

5.
Owen M, Sawa A, Mortensen P . Schizophrenia. Lancet. 2016; 388(10039):86-97. PMC: 4940219. DOI: 10.1016/S0140-6736(15)01121-6. View